Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Thera

[Business Wire] – Bristol-Myers Squibb Company and Pfizer Inc. today announced results from a post-hoc early time course subanalysis of the Phase 3 AMPLIFY trial. Read more on this. Bristol-Myers Squibb Company . . . → Read More: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Thera Similar Articles: Company Update (NYSE:BMY): Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab), the Only Treatment to Deliver Significant Overall Survival in Advanced Renal Cell Carcinoma vs. a Standard of Care, in Patients Who Have Received Prior Anti-Angiogenic Thera Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent Acute Coronary Syndrome or Undergoing Percutaneous Coronary In Market Update (NYSE:BMY): Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015